Dendritic Cell Based PSMA Immunotherapy for Prostate Cancer Using a CD40-Targeted Adenovirus Vector

Human prostate tumor vaccine and gene therapy trials using ex vivo methods to prime dendritic cells (DCs) with prostate specific membrane antigen (PSMA) have been somewhat successful, but to date the lengthy ex vivo manipulation of DCs has limited the widespread clinical utility of this approach. Ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Briana Jill, Bhatia, Shilpa, Adams, Lisa K., Boling, Susan, Carroll, Jennifer L., Li, Xiao-Lin, Rogers, Donna L., Korokhov, Nikolay, Kovesdi, Imre, Pereboev, Alexander V., Curiel, David T., Mathis, J. Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466199/
https://www.ncbi.nlm.nih.gov/pubmed/23056548
http://dx.doi.org/10.1371/journal.pone.0046981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466199/
https://www.ncbi.nlm.nih.gov/pubmed/23056548
http://dx.doi.org/10.1371/journal.pone.0046981

Ejemplares similares